These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 19070898)

  • 1. Methyltransferases in myelodysplastic syndromes: guilty or not guilty?
    Quesnel B
    Leuk Res; 2009 May; 33(5):601-2. PubMed ID: 19070898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms.
    Hopfer O; Komor M; Koehler IS; Freitag C; Schulze M; Hoelzer D; Thiel E; Hofmann WK
    Leuk Res; 2009 Mar; 33(3):434-42. PubMed ID: 18829110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arsenic Disulfide Promoted Hypomethylation by Increasing DNA Methyltransferases Expression in Myelodysplastic Syndrome.
    Zhou QB; Liu ZT; Wang HZ; Guo XQ; Xu YG; Hu XM
    Drug Des Devel Ther; 2020; 14():1641-1650. PubMed ID: 32431489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-regulation of DNA methyltransferases DNMT1, 3A, and 3B in myelodysplastic syndrome.
    Länger F; Dingemann J; Kreipe H; Lehmann U
    Leuk Res; 2005 Mar; 29(3):325-9. PubMed ID: 15661269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelodysplastic syndromes: molecular pathogenesis and genomic changes.
    Nolte F; Hofmann WK
    Ann Hematol; 2008 Oct; 87(10):777-95. PubMed ID: 18516602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Methylation status of LINE-1 sequences in patients with MDS or secondary AML].
    Römermann D; Hasemeier B; Metzig K; Schlegelberger B; Länger F; Kreipe H; Lehmann U
    Verh Dtsch Ges Pathol; 2007; 91():338-42. PubMed ID: 18314632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
    Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
    Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The expression of DNA methyltransferase DNMT1, 3A and 3B in acute leukemia and myelodysplastic syndrome].
    Li Y; Wu SL; Bu DF; Zhu Y; Zhu Q; Cao XH
    Zhonghua Nei Ke Za Zhi; 2003 Oct; 42(10):688-91. PubMed ID: 14633461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in multi-lineage and erythroid progenitors distinguishes myelodysplastic syndromes from non-malignant cytopenias.
    Vercauteren SM; Bashashati A; Wu D; Brinkman RR; Eaves C; Eaves A; Karsan A
    Leuk Res; 2009 Dec; 33(12):1636-42. PubMed ID: 19414193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation of promoters of microRNAs and their host genes in myelodysplastic syndromes.
    Erdogan B; Bosompem A; Peng D; Han L; Smith E; Kennedy ME; Alford CE; Wu H; Zhao Z; Mosse CA; El-Rifai W; Kim AS
    Leuk Lymphoma; 2013 Dec; 54(12):2720-7. PubMed ID: 23547841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of thiopurine drugs on DNA methylation in relation to TPMT expression.
    Hogarth LA; Redfern CP; Teodoridis JM; Hall AG; Anderson H; Case MC; Coulthard SA
    Biochem Pharmacol; 2008 Oct; 76(8):1024-35. PubMed ID: 18708030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylation and myelodysplastic syndromes: when and where?
    Quesnel B
    Leuk Res; 2006 Nov; 30(11):1327-9. PubMed ID: 16781771
    [No Abstract]   [Full Text] [Related]  

  • 13. The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes.
    Bacher U; Haferlach T; Kern W; Weiss T; Schnittger S; Haferlach C
    Cancer; 2009 Oct; 115(19):4524-32. PubMed ID: 19569249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
    Harada Y; Harada H
    J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular bases of myelodysplastic syndromes: lessons from animal models.
    Komeno Y; Kitaura J; Kitamura T
    J Cell Physiol; 2009 Jun; 219(3):529-34. PubMed ID: 19259975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetics in spermatogenesis.
    Trasler JM
    Mol Cell Endocrinol; 2009 Jul; 306(1-2):33-6. PubMed ID: 19481683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Realgar (α-As
    Zhang M; Zhang JY; Sun MQ; Lu P; Liu JX
    Chin J Integr Med; 2022 Mar; 28(3):281-288. PubMed ID: 32418175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired recruitment of the histone methyltransferase DOT1L contributes to the incomplete reactivation of tumor suppressor genes upon DNA demethylation.
    Jacinto FV; Ballestar E; Esteller M
    Oncogene; 2009 Nov; 28(47):4212-24. PubMed ID: 19734945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review.
    Oliansky DM; Antin JH; Bennett JM; Deeg HJ; Engelhardt C; Heptinstall KV; de Lima M; Gore SD; Potts RG; Silverman LR; Jones RB; McCarthy PL; Hahn T
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):137-72. PubMed ID: 19167676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.